Genincode PLC
LSE:GENI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vislink Technologies Inc
NASDAQ:VISL
|
US |
|
C
|
CSB Bank Ltd
NSE:CSBBANK
|
IN |
|
Keystone Law Group PLC
LSE:KEYS
|
UK |
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
G
|
Genincode PLC
LSE:GENI
|
8.3m GBP |
Loading...
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
100.2B USD |
Loading...
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
69.6B EUR |
Loading...
|
|
| US |
|
Cigna Corp
NYSE:CI
|
73.4B USD |
Loading...
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
25.1B EUR |
Loading...
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
23.8B EUR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
22.5B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.8B USD |
Loading...
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.2B EUR |
Loading...
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
11.4B USD |
Loading...
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.3B USD |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
Genincode PLC
Glance View
GENinCode UK Ltd. engages in the risk assessment and prediction of cardiovascular disease. The company is headquartered in Oxford, Oxfordshire. The company went IPO on 2021-07-22. The firm develops patented deoxyribonucleic acid (DNA) risk assessment products which utilize artificial intelligence (AI), bioinformatics and a globally recognized clinical evidence base to provide predictive analysis of a patient’s health risk. The Company’s clinical diagnostic tests cover global disease areas such as cardiovascular, cancer and diabetes.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Genincode PLC is -170.5%, which is above its 3-year median of -256.1%.
Over the last 3 years, Genincode PLC’s Net Margin has increased from -448.2% to -170.5%. During this period, it reached a low of -448.2% on Jun 30, 2022 and a high of -164.2% on Dec 31, 2024.
